{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "execution": {
     "iopub.execute_input": "2025-11-12T15:29:53.950905Z",
     "iopub.status.busy": "2025-11-12T15:29:53.950334Z",
     "iopub.status.idle": "2025-11-12T15:29:53.960026Z",
     "shell.execute_reply": "2025-11-12T15:29:53.959209Z",
     "shell.execute_reply.started": "2025-11-12T15:29:53.950874Z"
    },
    "trusted": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Helper functions defined.\n"
     ]
    }
   ],
   "source": [
    "# helper functions that will be reused throughout the notebook\n",
    "async def run_session(\n",
    "    runner_instance: Runner,\n",
    "    user_queries: list[str] | str = None,\n",
    "    session_name: str = \"default\",\n",
    "):\n",
    "    print(f\"\\n ### Session: {session_name}\")\n",
    "    app_name = runner_instance.app_name\n",
    "    try:\n",
    "        session = await session_service.create_session(\n",
    "            app_name=app_name, user_id=USER_ID, session_id=session_name\n",
    "        )\n",
    "    except:\n",
    "        session = await session_service.get_session(\n",
    "            app_name=app_name, user_id=USER_ID, session_id=session_name\n",
    "        )\n",
    "    if user_queries:\n",
    "        if type(user_queries) == str:\n",
    "            user_queries = [user_queries]\n",
    "        for query in user_queries:\n",
    "            print(f\"\\nUser > {query}\")\n",
    "            query = types.Content(role=\"user\", parts=[types.Part(text=query)])\n",
    "            async for event in runner_instance.run_async(\n",
    "                user_id=USER_ID, session_id=session.id, new_message=query\n",
    "            ):\n",
    "                if event.content and event.content.parts:\n",
    "                    if (\n",
    "                        event.content.parts[0].text != \"None\"\n",
    "                        and event.content.parts[0].text\n",
    "                    ):\n",
    "                        print(f\"{MODEL_NAME} > \", event.content.parts[0].text)\n",
    "    else:\n",
    "        print(\"No queries\")\n",
    "\n",
    "print(\"Helper functions defined.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "execution": {
     "iopub.execute_input": "2025-11-12T15:29:58.962602Z",
     "iopub.status.busy": "2025-11-12T15:29:58.962278Z",
     "iopub.status.idle": "2025-11-12T15:29:58.967410Z",
     "shell.execute_reply": "2025-11-12T15:29:58.966390Z",
     "shell.execute_reply.started": "2025-11-12T15:29:58.962575Z"
    },
    "trusted": true
   },
   "outputs": [],
   "source": [
    "retry_config = types.HttpRetryOptions(\n",
    "    attempts=5,  # Maximum retry attempts\n",
    "    exp_base=7,  # Delay multiplier\n",
    "    initial_delay=1,\n",
    "    http_status_codes=[429, 500, 503, 504],  # Retry on these HTTP errors\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<img src=\"https://storage.googleapis.com/github-repo/kaggle-5days-ai/day3/context-compaction.png\" width=\"1400\" alt=\"Context compaction\">"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# context compaction is needed to automatically summarize the previous events to avoid slower performance by using ADK's Context Compaction feature"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "execution": {
     "iopub.execute_input": "2025-11-12T15:38:02.918886Z",
     "iopub.status.busy": "2025-11-12T15:38:02.918440Z",
     "iopub.status.idle": "2025-11-12T15:38:02.928973Z",
     "shell.execute_reply": "2025-11-12T15:38:02.928015Z",
     "shell.execute_reply.started": "2025-11-12T15:38:02.918849Z"
    },
    "trusted": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Research App upgraded with Events Compaction!\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_134/3773147741.py:6: UserWarning: [EXPERIMENTAL] EventsCompactionConfig: This feature is experimental and may change or be removed in future versions without notice. It may introduce breaking changes at any time.\n",
      "  events_compaction_config=EventsCompactionConfig(\n"
     ]
    }
   ],
   "source": [
    "# re defining our app with Events Compaction enabled\n",
    "research_app_compacting = App(\n",
    "    name=\"research_app_compacting\",\n",
    "    root_agent=chatbot_agent,\n",
    "    # new part\n",
    "    events_compaction_config=EventsCompactionConfig(\n",
    "        compaction_interval=3,  # trigger compaction every 3 invocations\n",
    "        overlap_size=1,  # keep 1 previous turn for context\n",
    "    ),\n",
    ")\n",
    "\n",
    "db_url = \"sqlite:///my_agent_data.db\"  \n",
    "session_service = DatabaseSessionService(db_url=db_url)\n",
    "\n",
    "research_runner_compacting = Runner(\n",
    "    app=research_app_compacting, session_service=session_service\n",
    ")\n",
    "print(\"✅ Research App upgraded with Events Compaction!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# running a demo"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "execution": {
     "iopub.execute_input": "2025-11-12T15:38:39.131724Z",
     "iopub.status.busy": "2025-11-12T15:38:39.131045Z",
     "iopub.status.idle": "2025-11-12T15:38:58.653758Z",
     "shell.execute_reply": "2025-11-12T15:38:58.652740Z",
     "shell.execute_reply.started": "2025-11-12T15:38:39.131690Z"
    },
    "scrolled": true,
    "trusted": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > What is the latest news about AI in healthcare?\n",
      "gemini-2.5-flash-lite >  The field of AI in healthcare is experiencing rapid advancements. Here's a summary of some of the latest news and key areas of development:\n",
      "\n",
      "**1. Diagnostics and Imaging:**\n",
      "*   **AI for Image Analysis:** AI algorithms are becoming increasingly sophisticated at analyzing medical images like X-rays, CT scans, and MRIs. Recent news highlights AI's ability to detect subtle signs of diseases such as cancer, diabetic retinopathy, and cardiovascular conditions with accuracy comparable to or even exceeding human radiologists in some cases.\n",
      "*   **Early Disease Detection:** AI is being used to identify early warning signs of diseases from various data sources, including electronic health records (EHRs), genetic data, and even wearable device data. This allows for earlier intervention and potentially better patient outcomes.\n",
      "\n",
      "**2. Drug Discovery and Development:**\n",
      "*   **Accelerated Drug Discovery:** AI is revolutionizing drug discovery by speeding up the process of identifying potential drug candidates, predicting their efficacy and safety, and optimizing clinical trial design. Companies are using AI to analyze vast datasets of biological and chemical information to find novel treatments.\n",
      "*   **Personalized Medicine:** AI is crucial in developing personalized medicine approaches. By analyzing an individual's genetic makeup, lifestyle, and medical history, AI can help predict their response to different treatments and tailor therapies for maximum effectiveness.\n",
      "\n",
      "**3. Personalized Treatment and Patient Care:**\n",
      "*   **AI-Powered Treatment Planning:** AI is assisting clinicians in developing personalized treatment plans for patients, considering a multitude of factors to optimize care. This includes recommending the most effective therapies, dosages, and treatment sequences.\n",
      "*   **Virtual Health Assistants and Chatbots:** AI-powered chatbots and virtual assistants are becoming more prevalent, providing patients with information, appointment scheduling, medication reminders, and even basic symptom assessment. This can improve patient engagement and reduce the burden on healthcare providers.\n",
      "*   **Remote Patient Monitoring:** AI is enhancing remote patient monitoring by analyzing data from wearable devices and home health sensors to detect anomalies and alert healthcare professionals to potential issues, enabling proactive interventions.\n",
      "\n",
      "**4. Operational Efficiency and Administration:**\n",
      "*   **Streamlining Administrative Tasks:** AI is being deployed to automate administrative tasks such as medical coding, billing, appointment scheduling, and prior authorization, freeing up healthcare professionals to focus more on patient care.\n",
      "*   **Predictive Analytics for Hospital Operations:** Hospitals are using AI to predict patient flow, manage bed occupancy, optimize staffing, and identify potential bottlenecks, leading to improved efficiency and resource allocation.\n",
      "*   **Fraud Detection:** AI algorithms are being used to detect fraudulent claims and billing practices within the healthcare system.\n",
      "\n",
      "**5. Ethical and Regulatory Considerations:**\n",
      "*   **Data Privacy and Security:** As AI in healthcare relies on sensitive patient data, there's a continuous focus on ensuring robust data privacy and security measures are in place.\n",
      "*   **Bias in AI Algorithms:** Addressing bias in AI algorithms is a critical ongoing discussion. Ensuring fairness and equity in AI-driven healthcare decisions is paramount, and researchers are actively working to mitigate these biases.\n",
      "*   **Regulatory Approval:** Regulatory bodies like the FDA are actively developing frameworks for the approval and oversight of AI-powered medical devices and software, ensuring their safety and efficacy.\n",
      "\n",
      "**Recent Trends and Notable Developments:**\n",
      "\n",
      "*   **Generative AI in Healthcare:** Tools like large language models (LLMs) are showing promise in areas like summarizing medical literature, drafting clinical notes, and even assisting in medical education.\n",
      "*   **AI in Mental Health:** AI is being explored for early detection of mental health conditions, providing digital therapeutic interventions, and analyzing speech patterns for diagnostic clues.\n",
      "*   **AI for Medical Education and Training:** AI-powered simulations and personalized learning platforms are being developed to enhance the training of future healthcare professionals.\n",
      "\n",
      "It's important to note that while AI holds immense promise, it's still a developing field. Challenges remain in areas like data standardization, integration into existing workflows, and building trust among both healthcare professionals and patients.\n",
      "\n",
      "To get the absolute latest, I would recommend checking reputable healthcare technology news sources, medical journals, and reports from leading research institutions and companies in the AI and healthcare space.\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Are there any new developments in drug discovery?\n",
      "gemini-2.5-flash-lite >  Yes, there are many exciting new developments in drug discovery, with AI playing a central role in accelerating and revolutionizing the process. Here are some key areas and recent trends:\n",
      "\n",
      "**1. AI-Powered Target Identification and Validation:**\n",
      "*   **Mining Biological Data:** AI algorithms are becoming incredibly adept at sifting through massive datasets of genomic, proteomic, transcriptomic, and metabolomic information. They can identify novel disease-associated genes, proteins, or pathways that could serve as drug targets.\n",
      "*   **Predicting Target Druggability:** AI can assess whether a potential target is \"druggable\" – meaning it's feasible to design a molecule that can interact with it effectively to achieve a therapeutic effect. This helps prioritize targets that are more likely to lead to successful drug development.\n",
      "\n",
      "**2. Accelerated Molecule Design and Synthesis:**\n",
      "*   **Generative AI for Novel Molecules:** This is a huge area of progress. Generative AI models (similar to those used for creating text or images) can now design entirely new molecular structures with desired properties. They can explore chemical spaces that were previously too vast to search exhaustively.\n",
      "*   **De Novo Drug Design:** AI can design molecules \"from scratch\" that are optimized to bind to a specific target and possess favorable pharmacokinetic properties (how the body absorbs, distributes, metabolizes, and excretes the drug).\n",
      "*   **Predictive Synthesis:** AI is also helping predict the best chemical pathways to synthesize these newly designed molecules, reducing the time and cost associated with experimental chemistry.\n",
      "\n",
      "**3. Improved Efficacy and Safety Prediction:**\n",
      "*   **In Silico Screening:** Instead of physically testing millions of compounds in labs, AI can virtually screen vast libraries of existing and newly designed molecules to predict their potential efficacy against a disease target.\n",
      "*   **Predicting Off-Target Effects and Toxicity:** AI models are being trained to predict potential side effects and toxicity issues early in the discovery process, helping to filter out problematic drug candidates before they enter costly preclinical and clinical trials.\n",
      "*   **Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling:** AI enhances the understanding of how a drug will behave in the body (PK) and how it will exert its effect (PD), allowing for more informed dose selection and prediction of therapeutic outcomes.\n",
      "\n",
      "**4. Repurposing Existing Drugs:**\n",
      "*   **Identifying New Uses for Old Drugs:** AI can analyze existing drug data and disease information to identify potential new therapeutic applications for already approved drugs. This can significantly reduce the development timeline and cost, as safety data is already established.\n",
      "\n",
      "**5. Advancements in Clinical Trial Design and Patient Selection:**\n",
      "*   **Predicting Patient Response:** AI can analyze patient data to identify subgroups of patients who are most likely to respond to a particular drug. This leads to more targeted and efficient clinical trials.\n",
      "*   **Optimizing Trial Protocols:** AI can help design more efficient clinical trial protocols, predict enrollment rates, and identify potential risks or challenges.\n",
      "\n",
      "**Specific Examples and Trends:**\n",
      "\n",
      "*   **AlphaFold and Protein Structure Prediction:** DeepMind's AlphaFold has revolutionized our ability to predict the 3D structure of proteins. Knowing a protein's structure is crucial for understanding its function and designing drugs that can bind to it. This has opened up new avenues for drug discovery.\n",
      "*   **AI in Small Molecule and Biologic Drug Discovery:** AI is being applied to both traditional small molecule drugs and more complex biologics (like antibodies and proteins).\n",
      "*   **Increased Investment and Partnerships:** There's a significant surge in investment from venture capital and pharmaceutical companies in AI-driven drug discovery startups and collaborations. Major pharma companies are also building their internal AI capabilities.\n",
      "*   **Focus on Undruggable Targets:** AI is showing promise in tackling previously \"undruggable\" targets, which are difficult to design drugs for using traditional methods.\n",
      "\n",
      "**Challenges:**\n",
      "\n",
      "Despite the progress, challenges remain:\n",
      "*   **Data Quality and Availability:** The accuracy of AI models heavily relies on the quality and quantity of training data.\n",
      "*   **Interpretability:** Understanding *why* an AI model makes a certain prediction can be challenging, which is important for scientific validation and regulatory approval.\n",
      "*   **Integration into Existing Workflows:** Integrating AI tools seamlessly into the complex workflows of pharmaceutical R&D departments is an ongoing effort.\n",
      "*   **Validation:** Rigorous experimental validation is still essential for any AI-generated drug candidate.\n",
      "\n",
      "In summary, AI is fundamentally transforming drug discovery by making it faster, more efficient, and more predictive. We are seeing a shift from a trial-and-error approach to a more rational, data-driven design process, leading to the potential for new and better treatments for a wide range of diseases.\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Tell me more about the second development you found.\n",
      "gemini-2.5-flash-lite >  You're likely referring to the \"Accelerated Molecule Design and Synthesis\" development. This is indeed one of the most transformative areas of AI in drug discovery. Let me elaborate:\n",
      "\n",
      "**Accelerated Molecule Design and Synthesis: How AI is Reshaping the Search for New Drugs**\n",
      "\n",
      "Traditionally, discovering a new drug involved screening millions of existing chemical compounds or painstakingly synthesizing new ones, often through trial and error. This process is incredibly time-consuming, expensive, and has a high failure rate. AI is changing this paradigm by enabling **faster, more targeted, and more innovative molecule design.**\n",
      "\n",
      "Here's a breakdown of the key aspects:\n",
      "\n",
      "**1. Generative AI for Novel Molecules:**\n",
      "\n",
      "*   **What it is:** Imagine an AI that can \"invent\" new chemical structures. This is what generative AI is doing in drug discovery. These models are trained on vast datasets of known molecules and their properties. They learn the \"rules\" of chemistry and molecular design.\n",
      "*   **How it works:**\n",
      "    *   **Learning Chemical Space:** The AI learns the vast landscape of possible chemical structures and their relationships.\n",
      "    *   **Generating Candidates:** Given specific criteria (e.g., a target protein to bind to, desired solubility, low toxicity), the AI can generate entirely new molecular structures that are predicted to meet these requirements.\n",
      "    *   **Optimizing for Multiple Properties:** Instead of just finding a molecule that binds, generative AI can be tasked with designing molecules that simultaneously exhibit good binding affinity, desirable pharmacokinetic properties (absorption, distribution, metabolism, excretion), and low predicted toxicity.\n",
      "*   **Examples:**\n",
      "    *   **Deep Learning Models:** Models like Variational Autoencoders (VAEs), Generative Adversarial Networks (GANs), and recurrent neural networks (RNNs) are used to generate molecular strings (like SMILES notation) or molecular graphs.\n",
      "    *   **Reinforcement Learning:** This can be used to guide the generation process, rewarding the AI for creating molecules that better fit the desired profile.\n",
      "\n",
      "**2. De Novo Drug Design (Designing from Scratch):**\n",
      "\n",
      "*   **What it is:** This refers to creating a drug molecule without relying on existing templates or known drugs. The AI starts from a blank slate and designs a molecule specifically tailored to a particular biological target and therapeutic need.\n",
      "*   **How it works:**\n",
      "    *   **Target Structure Input:** The AI is given the 3D structure of the disease-causing protein (or other biological target).\n",
      "    *   **Binding Site Analysis:** The AI identifies potential binding pockets on the target.\n",
      "    *   **Designing Complementary Molecules:** The AI then designs molecules that are geometrically and chemically complementary to these binding sites, aiming for strong and specific interactions.\n",
      "*   **Significance:** This allows for the discovery of novel drug classes and approaches to diseases that may not have been addressable with existing chemical scaffolds.\n",
      "\n",
      "**3. Predictive Synthesis (How to Build It):**\n",
      "\n",
      "*   **The Challenge:** Designing a molecule is one thing; being able to actually synthesize it in a lab is another. Some theoretically designed molecules might be incredibly difficult or impossible to create using current chemical techniques.\n",
      "*   **AI's Role:** AI is being developed to predict viable synthetic routes for newly designed molecules.\n",
      "    *   **Retrosynthesis:** AI models can work backward from the target molecule, breaking it down into simpler precursor molecules and identifying known chemical reactions that can connect them.\n",
      "    *   **Predicting Reaction Yields and Conditions:** AI can also help predict the efficiency of different reactions and suggest optimal conditions (temperature, catalysts, solvents) for synthesis.\n",
      "*   **Impact:** This significantly reduces the time chemists spend figuring out how to make a compound, bridging the gap between theoretical design and practical realization.\n",
      "\n",
      "**Why is this \"Accelerated\"?**\n",
      "\n",
      "*   **Vastly Reduced Screening Time:** Instead of physically screening millions of compounds, AI can virtually screen and design billions of possibilities in a fraction of the time.\n",
      "*   **Higher Probability of Success:** By designing molecules with optimized properties from the outset, the likelihood of a candidate progressing through the development pipeline increases.\n",
      "*   **Discovery of Novel Chemical Space:** AI can explore chemical regions that human intuition or traditional methods might miss, leading to truly innovative drugs.\n",
      "*   **Reduced Cost:** Faster discovery and higher success rates translate to significant cost savings in R&D.\n",
      "\n",
      "This area of AI-driven molecule design and synthesis is a cornerstone of modern drug discovery, making it possible to tackle more complex diseases and develop therapies more efficiently than ever before.\n",
      "\n",
      " ### Session: compaction_demo\n",
      "\n",
      "User > Who are the main companies involved in that?\n",
      "gemini-2.5-flash-lite >  The landscape of companies involved in AI-driven drug discovery, particularly in molecule design and synthesis, is dynamic and includes a mix of **dedicated AI drug discovery startups, established pharmaceutical giants, and technology providers.**\n",
      "\n",
      "Here's a categorization of the main players:\n",
      "\n",
      "**1. Dedicated AI Drug Discovery Startups (Often leading the charge in molecule design):**\n",
      "\n",
      "These companies are built around AI-first approaches to drug discovery, with a strong focus on generating novel molecules.\n",
      "\n",
      "*   **Insilico Medicine:** Known for its generative AI platforms for target discovery and molecule design. They have advanced several AI-discovered drug candidates into clinical trials.\n",
      "*   **Exscientia:** Focuses on AI-driven drug design and has achieved significant milestones, including the first AI-designed drug to enter human clinical trials.\n",
      "*   **Recursion Pharmaceuticals:** Uses AI and automation to map human cellular biology and identify new drug targets and therapies. While not solely focused on molecule generation, their platform informs it.\n",
      "*   **Atomwise:** Specializes in using deep learning for small molecule drug discovery, including virtual screening and de novo design.\n",
      "*   **BenevolentAI:** Employs AI to mine scientific literature and biological data to identify novel drug targets and design new therapies.\n",
      "*   **Nurogene:** Another player focused on using AI for de novo drug design.\n",
      "*   **Schrödinger:** While an older company, Schrödinger has heavily invested in computational methods and AI for drug discovery, particularly in molecular modeling and property prediction, which informs molecule design.\n",
      "\n",
      "**2. Established Pharmaceutical Giants (Adopting and integrating AI):**\n",
      "\n",
      "Large pharmaceutical companies are rapidly building their internal AI capabilities and partnering with AI startups.\n",
      "\n",
      "*   **Pfizer:** Actively investing in AI for various aspects of drug discovery, including molecule design and clinical trial optimization.\n",
      "*   **Novartis:** Has a strong focus on AI and machine learning across its R&D operations, including drug design.\n",
      "*   **AstraZeneca:** Collaborating with AI companies and developing its own AI platforms for drug discovery and development.\n",
      "*   **Merck:** Exploring AI for target identification, lead optimization, and predictive modeling.\n",
      "*   **Sanofi:** Engaging in partnerships and internal initiatives to leverage AI in drug discovery.\n",
      "*   **Johnson & Johnson:** Utilizing AI and machine learning to accelerate research and development.\n",
      "*   **Gilead Sciences:** Exploring AI applications in identifying new therapeutic targets and designing drug candidates.\n",
      "\n",
      "**3. Technology and Cloud Providers (Enabling the infrastructure):**\n",
      "\n",
      "These companies provide the underlying AI platforms, computational power, and data infrastructure that many drug discovery companies rely on.\n",
      "\n",
      "*   **NVIDIA:** Their GPUs and AI software platforms (like Clara Discovery) are critical for the computationally intensive tasks in AI drug discovery, including molecular simulation and generative modeling.\n",
      "*   **Google (DeepMind/Google Cloud):** While DeepMind's AlphaFold is a prime example, Google Cloud offers AI/ML services that drug discovery companies can leverage for their computational needs.\n",
      "*   **Amazon Web Services (AWS):** Provides cloud computing infrastructure and AI/ML services that are essential for handling large datasets and complex computations in drug discovery.\n",
      "*   **Microsoft Azure:** Offers similar cloud and AI/ML services to support the computational demands of drug discovery.\n",
      "\n",
      "**4. Specialized AI/ML Software and Data Providers:**\n",
      "\n",
      "These companies offer specific AI tools or curated datasets for drug discovery.\n",
      "\n",
      "*   **Iktos:** Focuses on generative AI for de novo molecular design.\n",
      "*   **ChemAxon:** Provides cheminformatics software that can be integrated with AI tools for molecule analysis and design.\n",
      "\n",
      "**Key Trends in Company Involvement:**\n",
      "\n",
      "*   **Partnerships and Acquisitions:** Established pharma companies are increasingly partnering with or acquiring AI drug discovery startups to gain access to cutting-edge technology and talent.\n",
      "*   **In-house AI Teams:** Many large pharmaceutical companies are building significant in-house AI and data science teams to develop and deploy their own proprietary AI platforms.\n",
      "*   **Platform-as-a-Service (PaaS):** Some companies offer their AI drug discovery platforms as a service to other organizations.\n",
      "\n",
      "It's a rapidly evolving ecosystem, and new companies are emerging regularly. The trend is clear: AI is no longer a fringe technology in drug discovery; it's becoming an integral part of how new medicines are found and developed.\n"
     ]
    }
   ],
   "source": [
    "# turn 1\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"What is the latest news about AI in healthcare?\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# turn 2\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Are there any new developments in drug discovery?\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# turn 3\n",
    "# compaction should trigger after this turn\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Tell me more about the second development you found.\",\n",
    "    \"compaction_demo\",\n",
    ")\n",
    "\n",
    "# turn 4\n",
    "await run_session(\n",
    "    research_runner_compacting,\n",
    "    \"Who are the main companies involved in that?\",\n",
    "    \"compaction_demo\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# verifying compaction session history"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "execution": {
     "iopub.execute_input": "2025-11-12T15:39:09.679883Z",
     "iopub.status.busy": "2025-11-12T15:39:09.679594Z",
     "iopub.status.idle": "2025-11-12T15:39:09.691391Z",
     "shell.execute_reply": "2025-11-12T15:39:09.690554Z",
     "shell.execute_reply.started": "2025-11-12T15:39:09.679860Z"
    },
    "trusted": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Searching for Compaction Summary Event ---\n",
      "\n",
      "✅ SUCCESS! Found the Compaction Event:\n",
      "  Author: user\n",
      "\n",
      " Compacted information: model_version=None content=None grounding_metadata=None partial=None turn_complete=None finish_reason=None error_code=None error_message=None interrupted=None custom_metadata=None usage_metadata=None live_session_resumption_update=None input_transcription=None output_transcription=None avg_logprobs=None logprobs_result=None cache_metadata=None citation_metadata=None invocation_id='5f8f02a6-c646-4d2b-a923-7f53751442d6' author='user' actions=EventActions(skip_summarization=None, state_delta={}, artifact_delta={}, transfer_to_agent=None, escalate=None, requested_auth_configs={}, requested_tool_confirmations={}, compaction={'start_timestamp': 1762961919.164185, 'end_timestamp': 1762961928.80695, 'compacted_content': {'parts': [{'function_call': None, 'code_execution_result': None, 'executable_code': None, 'file_data': None, 'function_response': None, 'inline_data': None, 'text': 'The user asked for the latest news in AI in healthcare. The AI agent provided a comprehensive overview covering diagnostics, drug discovery, personalized treatment, operational efficiency, and ethical considerations. Key trends included generative AI in healthcare and AI for mental health.\\n\\nThe user then inquired about new developments in drug discovery. The AI agent highlighted AI\\'s role in accelerating this process through target identification, accelerated molecule design (using generative AI and de novo design), improved efficacy/safety prediction, drug repurposing, and advancements in clinical trial design. Notable examples included AlphaFold and increased investment in AI-driven drug discovery. Challenges like data quality, interpretability, and integration were also mentioned.\\n\\nFinally, the user requested more details on \"Accelerated Molecule Design and Synthesis.\" The AI agent explained this development in depth, focusing on:\\n*   **Generative AI for Novel Molecules:** How AI \"invents\" new chemical structures with desired properties.\\n*   **De Novo Drug Design:** Creating drug molecules from scratch tailored to specific targets.\\n*   **Predictive Synthesis:** AI assisting in determining how to chemically synthesize these newly designed molecules.\\n\\nThe agent emphasized that these AI capabilities significantly reduce screening time, increase the probability of success, allow exploration of novel chemical spaces, and ultimately lower R&D costs. No unresolved questions or tasks remain from this conversation history.', 'thought': None, 'thought_signature': None, 'video_metadata': None}], 'role': 'model'}}, end_of_agent=None, agent_state=None, rewind_before_invocation_id=None) long_running_tool_ids=set() branch=None id='660f430c-ff73-4b30-b535-97c483c93633' timestamp=1762961935.949315\n"
     ]
    }
   ],
   "source": [
    "# G=get the final session state\n",
    "final_session = await session_service.get_session(\n",
    "    app_name=research_runner_compacting.app_name,\n",
    "    user_id=USER_ID,\n",
    "    session_id=\"compaction_demo\",\n",
    ")\n",
    "print(\"--- Searching for Compaction Summary Event ---\")\n",
    "found_summary = False\n",
    "for event in final_session.events:\n",
    "    # compaction events have a 'compaction' attribute\n",
    "    if event.actions and event.actions.compaction:\n",
    "        print(\"\\n✅ SUCCESS! Found the Compaction Event:\")\n",
    "        print(f\"  Author: {event.author}\")\n",
    "        print(f\"\\n Compacted information: {event}\")\n",
    "        found_summary = True\n",
    "        break\n",
    "\n",
    "if not found_summary:\n",
    "    print(\n",
    "        \"\\n❌ No compaction event found. Try increasing the number of turns in the demo.\"\n",
    "    )"
   ]
  }
 ],
 "metadata": {
  "kaggle": {
   "accelerator": "none",
   "dataSources": [],
   "isGpuEnabled": false,
   "isInternetEnabled": true,
   "language": "python",
   "sourceType": "notebook"
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
